Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Korotych O, et al. Among authors: yedilbayev a. Lancet Infect Dis. 2024 Oct;24(10):1151-1161. doi: 10.1016/S1473-3099(24)00228-7. Epub 2024 Jun 13. Lancet Infect Dis. 2024. PMID: 38880112 Free PMC article.
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.
Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. Velásquez GE, et al. Among authors: yedilbayev a. Clin Infect Dis. 2014 Jul 1;59(1):9-15. doi: 10.1093/cid/ciu209. Epub 2014 Apr 11. Clin Infect Dis. 2014. PMID: 24729493 Free PMC article.
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB. Borisov S, et al. Among authors: yedilbayev a. Eur Respir J. 2019 Dec 19;54(6):1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31601711 Free article.
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison C, Islam S, Khachatryan N, Kotrikadze T, Khan U, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich M, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD. Seung KJ, et al. Among authors: yedilbayev a. Clin Infect Dis. 2020 Jul 11;71(2):415-418. doi: 10.1093/cid/ciz1084. Clin Infect Dis. 2020. PMID: 31676905
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network. Migliori GB, et al. Int J Infect Dis. 2020 Mar;92S:S15-S25. doi: 10.1016/j.ijid.2020.01.042. Epub 2020 Feb 4. Int J Infect Dis. 2020. PMID: 32032752 Free article. Review.
What is behind programmatic treatment outcome definitions for tuberculosis?
Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M, Vasilyeva I, Vilc V, Yedilbayev A. Avaliani Z, et al. Among authors: yedilbayev a. Eur Respir J. 2020 Jul 23;56(1):2001751. doi: 10.1183/13993003.01751-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32703821 Free article. No abstract available.
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V, Kumar AMV, Hurevich H, Sereda Y, Auchynka V, Katovich D, Klimuk D, Skrahin A, Setkina S, Charnysh I, Yedilbayev A, Skrahina A. Solodovnikova V, et al. Among authors: yedilbayev a. Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1646. Monaldi Arch Chest Dis. 2021. PMID: 33470080 Free article.
37 results